# US 2004/0082501 A1 · Compounds and method for the prevention and treatment of diabetic retinopathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082501 A1
- Document ID: US20040082501A1
- Status: Published application
- Kind: A1
- Application number: 10/412,603
- Filed: 2003-04-11
- Published: 2004-04-29
- Earliest claimed: 1997-09-10
- Assignees: University of Florida
- Inventors: Nicholas Stephen Bodor; Maria Grant
- Web page: https://patentgrep.com/patent/US20040082501A1

## CPC

- C07K 14/655: Somatostatins
- A61K 47/559: {Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides peptide derivatives designed to deliver peptides having growth factor inhibitory activity, especially somatostatin analogs, to the retina by sequential metabolism. The peptide derivatives, which comprise a dihydropyridine⇄pyridinium salt-type redox targetor moiety, a bulky lipophilic function and an amino acid/dipeptide/tripeptide spacer, are used in the prevention and treatment of diabetic retinopathy.

## Claims

### Claim 1

A compound of the formula
79
or a non-toxic pharmaceutically acceptable salt thereof, wherein:
R1 is C1-C7 alkyl, C1-C7 haloalkyl or C7-C12 aralkyl;
R2 and R3, which are the same or different, are each selected from the group consisting of hydrogen, halo, cyano, C1-C7 alkyl, C1-C7 alkoxy, C2-C8 alkoxycarbonyl, C2-C8 alkanoyloxy, C1-C7 haloalkyl, C1-C7 alkylthio, C1-C7 alkylsulfinyl, C1-C7 alkylsulfonyl, —CH═NOR′″ wherein R′″ is hydrogen or C1-C7 alkyl, and —CONR′R″ wherein R′ and R″, which are the same or different, are each hydrogen or C1-C7 alkyl;
or one of R2 and R3 together with the adjacent ring carbon atom forms a phenyl ring fused to the six-membered heterocyclic ring, which phenyl ring is unsubstituted or is substituted with one or two substituents, which are the same or different, selected from the group consisting of hydroxy, protected hydroxy, halo, cyano, C1-C7 alkyl, C1-C7 alkoxy, C2-C8 alkoxycarbonyl, C2-C8 alkanoyloxy, C1-C7 haloalkyl, C1-C7 alkylthio, C1-C7 alkylsulfinyl, C1-C7 alkylsulfonyl, —CH═NOR′″ wherein R′″ is hydrogen or C1-C7 alkyl, and —CONR′R″ wherein R′ and R″, which are the same or different, are each hydrogen or C1-C7 alkyl;
the depicted ring system is a pyridinium, quinolinium or isoquinolinium ion;
“spacer” is an L-amino acid unit or a di- or tripeptide consisting of 2 or 3 L-amino acid units, the N-terminal amino acid of said spacer being bonded to the depicted carbonyl carbon via an amide bond;
and “peptide” is a peptide having 2 to 20 amino acid units having growth factor inhibitory activity which is octreotide or lanreotide, wherein the N-terminal phenylalanine or napthylalanine of said peptide is bonded to the C-terminal amino acid of said spacer via a peptide bond, and wherein the C-terminal threonine of said peptide:
(a) has a C-terminal carboxyl group —COOH which has been replaced with a —COOR4 group wherein R4 is C6-C30 polycycloalkyl-CpH2p— wherein p is 0, 1, 2 or 3, or C6-C30 polycycloalkenyl-CpH2p— wherein p is defined as above;
(b) has a C-terminal —CH2OH group which has been replaced with a —CH2OCOR4 group wherein R4 is defined as above;
(c) has a C-terminal —CONH2 group which has been replaced with a —CO-Gly-OR4 group wherein R4 is defined as above, said —CO-Gly-OR4 group regenerating the C-terminal —CONH2 group in vivo;
(d) has a C-terminal —CONH2 group; or
(e) has a C-terminal —CH2OH group;
with the provisos that:
(1) when the C-terminal amino acid is as defined in (a), (b) or (c) above, the side chain —NH2 group of lysine of the peptide is replaced with a —NHCOOR5 group wherein R5 is C1-C7 alkyl or benzyl; and
(2) when the C-terminal amino acid is as defined in (d) or (e) above, then the side chain —N2 group of lysine of the peptide is replaced with a —NHCOOR4 group wherein R4 is defined as above.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein the depicted ring system is a 1,4-dihydroquinoline, 1,2-dihydroquinoline or 1,2-dihydroisoquinoline.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein R5 is t-butyl.

### Claim 4 (depends on 1)

A compound according to claim 1, wherein the peptide is lanreotide.

### Claim 5 (depends on 1)

A compound according to claim 1, wherein the peptide is octreotide and wherein the octreotide's C-terminal —CH2OH group has been replaced with a —CH2OCOR4 group and wherein the free amino group —NH2 of the Lys unit of octreotide has been replaced with a —NHCOOR5 group.

### Claim 6 (depends on 4)

A compound according to claim 4, wherein lanreotide's C-terminal —CONH2 group has been replaced with a —CO-Gly-OR4 group and wherein the free amino group —NH2 of the Lys unit of lanreotide has been replaced with a —NHCOOR5 group.

### Claim 7 (depends on 4)

A compound according to claim 4, wherein lanreotide has its C-terminal —CONH2 group unchanged and wherein the free amino group —NH2 of the Lys unit of lanreotide has been replaced with a —NHCOOR4 group.

### Claim 8 (depends on 1)

A compound according to claim 1, wherein R4 is a radical of the formula
80
wherein R6 is C1-C7 alkyl.

### Claim 9 (depends on 8)

A compound according to claim 8, wherein R6 is methyl.

### Claim 10 (depends on 1)

A compound according to claim 1, wherein R4 is —CpH2p-adamantyl.

### Claim 11 (depends on 10)

A compound according to claim 10, wherein R4 is
81

### Claim 12

A compound of the formula
82
or a non-toxic pharmaceutically acceptable salt thereof, wherein:
R1 is C1-C7 alkyl, C1-C7 haloalkyl or C7-C2 aralkyl;
R2 and R3, which are the same or different, are each selected from the group consisting of hydrogen, halo, cyano, C1-C7 alkyl, C1-C7 alkoxy, C2-C8 alkoxycarbonyl, C2-C8 alkanoyloxy, C1-C7 haloalkyl, C1-C7 alkylthio, C1-C7 alkylsulfinyl, C1-C7 alkylsulfonyl, —CH═NOR′″ wherein R′″ is hydrogen or C1-C7 alkyl, and —CONR′R″ wherein R′ and R″, which are the same or different, are each hydrogen or C1-C7 alkyl;
or one of R2 and R3 together with the adjacent ring carbon atom forms a phenyl ring fused to the six-membered heterocyclic ring, which phenyl ring is unsubstituted or is substituted with one or two substituents, which are the same or different, selected from the group consisting of hydroxy, protected hydroxy, halo, cyano, C1-C7 alkyl, C1-C7 alkoxy, C2-C8 alkoxycarbonyl, C2-C8 alkanoyloxy, C1-C7 haloalkyl, C1-C7 alkylthio, C1-C7 alkylsulfinyl, C1-C7 alkylsulfonyl, —CH═NOR′″ wherein R′″ is hydrogen or C1-C7 alkyl, and —CONR′R″ wherein R′ and R″, which are the same or different, are each hydrogen or C1-C7 alkyl;
the depicted ring system is a pyridinium, quinolinium or isoquinolinium ion;
“spacer” is an L-amino acid selected from the group consisting of alanine and proline, or a dipeptide consisting of L-amino acid units selected from said group, the N-terminal amino acid of said spacer being bonded to the depicted carbonyl carbon via an amide bond;
and “peptide” is a peptide having 2 to 20 amino acid units having growth factor inhibitory activity which is octreotide or lanreotide, wherein the N-terminal phenylalanine or napthylalanine of said peptide is bonded to the C-terminal amino acid of said spacer via a peptide bond, and wherein the C-terminal threonine of said peptide:
(a) has a C-terminal carboxyl group —COOH which has been replaced with a —COOR4 group wherein R4 is C6-C30 polycycloalkyl-CpH2p— wherein p is 0, 1, 2 or 3, or C6-C30 polycycloalkenyl-CpH2p— wherein p is defined as above;
(b) has a C-terminal —CH2OH group which has been replaced with a —CH2OCOR4 group wherein R4 is defined as above;
(c) has a C-terminal —CONH2 group which has been replaced with a —CO-Gly-OR4 group wherein R4 is defined as above, said —CO-Gly-OR4 group regenerating the C-terminal —CONH2 group in vivo;
(d) has a C-terminal —CONH2 group; or
(e) has a C-terminal —CH2OH group;
with the provisos that:
(1) when the C-terminal amino acid is as defined in (a), (b) or (c) above, the side chain —NH2 group of lysine of the peptide is replaced with a —NHCOOR5 group wherein R5 is C1-C7 alkyl or benzyl; and
(2) when the C-terminal amino acid is as defined in (d) or (e) above, then the side chain —NH2 group of the peptide is replaced with a —NHCOOR4 group wherein R4 is defined as above.

### Claim 13 (depends on 12)

A compound according to claim 12, wherein the depicted ring system is a 1,4-dihydroquinoline, 1,2-dihydroquinoline or 1,2-dihydroisoquinoline.

### Claim 14 (depends on 12)

A compound according to claim 12, wherein R5 is t-butyl.

### Claim 15 (depends on 12)

A compound according to claim 12, wherein the peptide is lanreotide.

### Claim 16 (depends on 12)

A compound according to claim 12, wherein the peptide is octreotide and wherein the octreotide's C-terminal —CH2OH group has been replaced with a —CH2OCOR4 group and wherein the free amino group —NH2 of the Lys unit of octreotide has been replaced with a —NHCOOR5 group.

### Claim 17 (depends on 15)

A compound according to claim 15, wherein lanreotide's C-terminal —CONH2 group has been replaced with a —CO-Gly-OR4 group and wherein the free amino group —NH2 of the Lys unit of lanreotide has been replaced with a —NHCOOR5 group.

### Claim 18 (depends on 15)

A compound according to claim 15, wherein lanreotide has its C-terminal —CONH2 group unchanged and wherein the free amino group —NH2 of the Lys unit of lanreotide had been replaced with a —NHCOOR4 group.

### Claim 19 (depends on 12)

A compound according to claim 12, wherein R4 is —CpH2p-steryl wherein p is 0.

### Claim 20 (depends on 19)

A compound according to claim 19, wherein R4 is a radical of the formula
83
wherein R6 is C1-C7 alkyl.

### Claim 21 (depends on 20)

A compound according to claim 20, wherein R6 is methyl.

### Claim 22 (depends on 12)

A compound according to claim 12, wherein R4 is —CpH2p-adamantyl.

### Claim 23 (depends on 22)

A compound according to claim 22, wherein R4 is
84

### Claim 24 (depends on 15)

A compound according to claim 15, wherein R4 is —CpH2p-steryl or —CpH2p-adamantyl.

### Claim 25 (depends on 16)

A compound according to claim 16, wherein R4 is —CpH2p-steryl or —CpH2p-adamantyl.

### Claim 26 (depends on 21)

A compound according to claim 21, wherein the peptide is octreotide and wherein R4 is —CpH2p-steryl or —CpH2p-adamantyl.

### Claim 27 (depends on 17)

A compound according to claim 17, wherein R4 is —CpH2p-steryl or —CpH2p-adamantyl.

### Claim 28 (depends on 18)

A compound according to claim 18, wherein R4 is —CpH2p-steryl or —CpH2p-adamantyl.

### Claim 29 (depends on 16)

The compound according to claim 16, having the formula
85

### Claim 30 (depends on 17)

The compound according to claim 17, having the formula
86

### Claim 31 (depends on 18)

The compound according to claim 18, having the formula
87
